$64.00
You’ll be briefly redirected to Link Money, our secure ACH payment partner, to connect your bank and complete payment.– Your bank login is never visible to or stored by us – Encrypted, bank-level security – A standard, trusted payment process
Delta Sleep–Inducing Peptide (DSIP) is primarily studied for its role in sleep regulation, particularly delta wave activity associated with deep, restorative sleep. Research examines how DSIP may influence sleep architecture, REM cycles, circadian rhythms, and neurochemical signaling pathways involved in inhibitory neurotransmission. These studies are strictly experimental and focused on understanding sleep mechanisms.
Yes. DSIP frequently appears in preclinical research exploring stress response, emotional regulation, and behavioral outcomes linked to disrupted sleep. Some studies also investigate DSIP indirectly in pain and chronic pain models, primarily by evaluating how sleep quality and stress modulation affect pain perception rather than through direct analgesic effects.
DSIP research is typically conducted using controlled animal models, most commonly rats and rabbits. These studies evaluate sleep patterns, delta wave activity, hormonal signaling, withdrawal symptoms, and behavioral responses. Research also explores whether DSIP interacts with central nervous system pathways, including investigations into its relationship with the blood-brain barrier.
No. DSIP is not approved for human consumption, medical treatment, or therapeutic use in the United States. Any references to DSIP injections, intravenous use, or therapy exist only in historical or experimental literature. For research purposes, DSIP is supplied as a lyophilized peptide and handled according to institutional laboratory protocols, without dosing or administration guidance.
